

RADIATION FORUM

CHELSEA HOTEL, TORONTO, ON
 ROOM: WREN
 FRIDAY, APRIL 27TH, 2018 – 8:00 AM – 12:00 PM

CHAIR: M. MCKENZIE
 SENIOR INVESTIGATOR: WENDY PARULEKAR
 STUDY COORDINATORS: ALEXANDER MONTENEGRO & KATE WHELAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to solid tumours and haematological malignancies treated with radiotherapy.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials or its collaborators.
- To provide a learning environment supportive to new investigators.
- To interpret and apply new clinical trial methodologies in the field of clinical research in Canada

8:00 am	Welcome	M. McKenzie
	<u>CCTG Led Open trials</u>	
8:05 am	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. HE.1	L. Dawson
8:15 am	Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. PR.19	G. Morton/ E. Vigneault
8:25 am	SBRT vs. Conventional Palliative Radiotherapy for Spinal Metastases. SC.24	A. Sahgal
8:35 am	Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and brain metastases. IND.224	A. Sahgal
8:45 am	Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Adjuvant Durvalumab vs Durvalumab + RT followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). HN.9	K. Sultanem

continued on next page ...

CCTG Intergroup Open trials

- | | | |
|---------|--|----------|
| 8:55 am | Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. GA.1 | R. Wong |
| 9:05 am | Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. CEC.5 | C. Chung |

Updates on previously discussed studies/proposals

- | | | |
|---------|---|---------------------|
| 9:15 am | Phase III Trial of Local Ablative Therapy or not for Hormone Sensitive Oligometastatic Prostate Cancer. | T. Niazi/ P. Cheung |
| 9:25 am | PRIME Study - Prevention and intervention for metabolic syndrome | N. Usmani |

Coffee Break

Updates on CCTG studies pending of activation

- | | | |
|----------|---|-------------|
| 10:00 am | A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. HN.10 | S. Bratman |
| 10:10 am | TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. MA.39 | V. Theberge |
| 10:20 am | A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases CE.7 | D. Roberge |

New Study proposals

- | | | |
|----------|--|---------------------------|
| 10:30 am | CCTG Radiotherapy Strategic Agenda | M. Brundage/ W. Parulekar |
| 10:50 am | Stereotactic Pelvic Adjuvant Radiation TherApy in Cancers of the UteruS (SPARTACUS). | E. Leung |
| 11:00 am | SBRT for non-spine metastasis? | A. Sahgal |
| 11:10 am | PSMA-PET Guided Radiotherapy in Patients with High-risk, Recurrent, or Oligometastatic Prostate Cancer. | C. Menard |
| 11:20 am | NRG HN004 Randomized ph 2/3 trial of RT+Duravlumab vs RT+Cetuximab in Stage 3-4B head and neck cancer with cisplatin contraindication. | J. Waldron |
| 11:30 am | Prophylaxis of radiation induced nausea and vomiting: a double-blind controlled randomized trial of palonosetron vs. granisetron. | E. Chow |
| 11:40 am | Darolutamide to Augment Standard Therapy for Localized High-Risk Cancer of the Prostate (DASLHiCaP). | T. Niazi |
| 11:50 am | Activities of the Radiation Oncology Quality Assurance Committee | A. Nichol |

12:00 pm **Meeting adjourned.**